Cao Ning, Dang Wenxi, Xin Yanguo, Li Jiayu, Guo Shaohua, Li Qitian, Chen Hui, Li Shun
Department of Cardiology, Cardiovascular Centre, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Laboratory of Clinical Medicine, Capital Medical University, 331 Xitieying, Youanmen, Fengtai District, Beijing, 100069, China.
J Transl Autoimmun. 2024 Nov 14;9:100261. doi: 10.1016/j.jtauto.2024.100261. eCollection 2024 Dec.
Coronary microvascular obstruction (MVO) frequently occurs in patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI), leading to poor prognosis. β adrenergic receptor autoantibodies (β-AA) are present in various cardiovascular diseases and correlate with cardiac damage and dysfunction. However, whether β-AA is associated with the occurrence of MVO in patients with STEMI after PCI remains unclear.
To investigate the prognostic relationship between β-AA and the occurrence of MVO in patients with STEMI with post-PCI.
This prospective study included 403 patients with STEMI who underwent primary PCI. The patients were divided into MVO+ and MVO- groups. Serum β-AA levels were measured prior to primary PCI. The primary outcome was MVO, assessed through cardiac magnetic resonance imaging at 5-7 days after PCI.
A total of 127 MVO+ and 276 MVO- patients were identified. Patients with MVO + exhibited higher β-AA optical density (OD) compared to MVO- patients. β-AA OD, pNT-proBNP, pCK-MB and pTNI were positively associated with MVO following PCI. Notably, the assocition between β-AA levels and MVO risk strengthened with increasing pNT-proBNP levels. The combination of β-AA, pNT-proBNP and pTNI yielded the most efficient MVO prediction with an area under the ROC curve of 0.87 (95 % CI: 0.83-0.90).
β-AA is significantly associated with the occurrence of MVO in STEMI patients following primary PCI. The combination of β-AA with pNT-proBNP and pTNI improves predictive accuracy, providing a more robust and effective strategy for assessing MVO risk.
冠状动脉微血管阻塞(MVO)在经皮冠状动脉介入治疗(PCI)后的ST段抬高型心肌梗死(STEMI)患者中经常发生,导致预后不良。β肾上腺素能受体自身抗体(β-AA)存在于多种心血管疾病中,并与心脏损伤和功能障碍相关。然而,β-AA是否与PCI术后STEMI患者MVO的发生有关仍不清楚。
探讨β-AA与PCI术后STEMI患者MVO发生的预后关系。
这项前瞻性研究纳入了403例行直接PCI的STEMI患者。将患者分为MVO+组和MVO-组。在直接PCI术前测量血清β-AA水平。主要结局为MVO,在PCI术后5-7天通过心脏磁共振成像评估。
共识别出127例MVO+患者和276例MVO-患者。与MVO-患者相比,MVO+患者的β-AA光密度(OD)更高。PCI术后,β-AA OD、pNT-proBNP、pCK-MB和pTNI与MVO呈正相关。值得注意的是,随着pNT-proBNP水平的升高,β-AA水平与MVO风险之间的关联增强。β-AA、pNT-proBNP和pTNI联合使用对MVO的预测效率最高,ROC曲线下面积为0.87(95%CI:0.83-0.90)。
β-AA与直接PCI术后STEMI患者MVO的发生显著相关。β-AA与pNT-proBNP和pTNI联合使用可提高预测准确性,为评估MVO风险提供更可靠有效的策略。